Beta Device for Detecting Cervical Cancer

The developer of a new, noninvasive device for the detection of cervical cancer has announced that the first pre-production model has been successfully built and tested.

This next-generation device contains major components planned for use in commercial production. The single-patient-use disposables are made of molded plastic and contain the calibration material that is expected to be used in the final commercial product. The work on the device was initiated by SpectRx (Norcross, GA, USA), a diabetes-management company. A subsidiary of the company, Guided Therapeutics, Inc. (Norcross, GA, USA), is developing and will market the device.

The device uses proprietary technology to identify cancers and precancers painlessly and noninvasively by analyzing light reflected from the cervix. An image of the cervix created by the device highlights the location and severity of disease. The technology can distinguish between normal and disease tissue by detecting biochemical and morphologic changes at the cellular level. No tissue samples are needed, and results are available immediately.

"We are pleased with the initial technical performance of the advances in the pre-production device and single-use disposable, both of which will benefit from advances in our patented technology and component optimization,” observed Mark Faupel, president and COO of Guided Therapeutics. "Additionally, we believe that this new-generation system will enable us to reach our price-of-production goals, thus making the technology affordable to the general ob/gyn [obstetrician/gynecologist] and family practice physician.





Related Links:
SpectRx
Guided Therapeutics